首页> 外文OA文献 >PCV103 The Cost-Effectiveness Of Novel Oral Anticoagulants For The Prevention Of Stroke In Atrial Fibrillation In England And Wales

【2h】

PCV103 The Cost-Effectiveness Of Novel Oral Anticoagulants For The Prevention Of Stroke In Atrial Fibrillation In England And Wales

机译：PCV103新型口服抗凝剂在英格兰和威尔士预防房颤中风的成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Thom H; Hollingworth W; Bryden PA; Sterne J; Bodalia PN; Davies P; Lopez-Lopez JA; Okoli GN; Caldwell DM; Dias S; Eaton D; Higgins J; Salisbury C; Savovic J; Sofat R; Stephens-Boal A; Hingorani A; Welton NJ;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis [J] . Howard H. Z. Thom, Will Hollingworth, Reecha Sofat, MDM Policy & Practice . 2019,第2期

机译：直接代替口腔抗凝血剂，用于预防英国和威尔士的心房颤动：成本效益模型和信息分析价值
2. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group [J] . Pharithi Rebabonye B., Ranganathan Deepti, OBrien Jim, Irish journal of medical science . 2019,第1期

机译：处方是否正确？非瓣膜心房颤动患者的非维生素K拮抗剂抗凝血剂（NOAC）处方述评。心房颤动和卒中中非维生素K口腔抗凝血剂的心房颤动和评价安全规定（安全Noacs）组
3. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand [J] . Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis . 2020,第期

机译：泰国心房颤动患者中风预防的华法素护理捆绑和新口腔抗凝血剂的成本效益
4. What Is the Best Practical Scheme for Initiating Oral Anticoagulant Treatment in Outpatients with Atrial Fibrillation? [C] . R. CAZZIN, P. SERRA, C. FUSILLI International Workshop on Cardiac Arrhythmias . 2004

机译：在心房颤动的门诊患者中启动口服抗凝血治疗的最佳实用方案是什么？
5. Cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the United States [D] . Alhazami, Mai S. 2015

机译：在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
6. Directly Acting Oral Anticoagulants for the Prevention of Stroke inAtrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value ofInformation Analysis [O] . Howard H. Z. Thom, Will Hollingworth, Reecha Sofat, 2019

机译：直接作用的口服抗凝剂预防中风英格兰和威尔士的心房颤动：成本-效果模型和价值信息分析
7. Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis [O] . Howard H. Z. Thom, Will Hollingworth, Reecha Sofat, 2019

机译：直接代替口腔抗凝血剂，用于预防英国和威尔士的心房颤动：成本效益模型和信息分析价值

PCV103 The Cost-Effectiveness Of Novel Oral Anticoagulants For The Prevention Of Stroke In Atrial Fibrillation In England And Wales

著录项

引文网络

相似文献

相关主题

期刊订阅